Raymond James Financial Services Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-13,892	Closed	-$329K	–	2986
2019 Q3	$329K	Sell	13,892 -15,859	-53%	-$470K	﹤0.01%	2188
2019 Q2	$895K	Buy	29,751 +6,538	+28%	+$150K	﹤0.01%	1567
2019 Q1	$520K	Sell	23,213 -16,072	-41%	-$346K	﹤0.01%	1881
2018 Q4	$715K	Buy	39,285 +26,985	+219%	+$424K	﹤0.01%	1449
2018 Q3	$223K	Buy	+12,300	New	+$146K	﹤0.01%	2463

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial Services Advisors's RARX Position: Q4 2019 in Review

Raymond James Financial Services Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 13,892 shares — an estimated $329K sold.

Raymond James Financial Services Advisors first reported a position in RARX in Q3 2018 and held it in 5 quarters. The position peaked at $895K in Q2 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

Raymond James Financial Services Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Raymond James Financial Services Advisors sold 13,892 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $329K.
Raymond James Financial Services Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 5 quarters.
Raymond James Financial Services Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $895K in Q2 2019.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.